Background and Aims: This study aims to determine the rate of combined central and peripheral demyelination (CCPD), compare its clinical, radiological, and electrophysiological features with CNS demyelinating diseases and CIDP, and assess the role of Neurofascin‐155 (NF‐155) and myelin oligodendrocyte glycoprotein (MOG) antibodies. This evidence concerns the gene MOG and demyelinating disease of central nervous system.